We have recently published a new article about γδ T cells in chronic lymphocytic leukaemia. For the full article please click here. We observed a dysregulation of CD155 – TIGIT/DNAM-1 pathway. While CD226 (DNAM-1) was decreased on γδ T, TIGIT had higher expression. At the same time, CD155, a ligand of both DNAM-1 and TIGIT, was significantly overexpressed by leukaemic cells. Altogether this suggests a possible usefulness of TIGIT inhibitors as future therapeutics in chronic lymphocytic leukaemia.
